Chest
Original ResearchCOPDSerum IP-10 as a Biomarker of Human Rhinovirus Infection at Exacerbation of COPD
Section snippets
Patient Recruitment
One hundred thirty-six patients were studied between April 1, 2006, and May 31, 2008. Seventy smoking and nonsmoking control subjects of similar age but without COPD were recruited from a primary care practice. The recruitment and monitoring of patients in the London COPD study has previously been described2, 4, 12, 13, 14 and further details are available in the online supplement. This study was approved by the Royal Free Hospital Research Ethics Committee and patients gave written informed
Baseline Patient Characteristics
One hundred thirty six patients with COPD were studied (83 men and 53 women). The baseline characteristics of the cohort are reported in Table 1. The patients had a mean FEV1 of 1.16 l or 53.9% predicted.
Seventy control subjects were studied (28 men and 42 women). The baseline characteristics are reported in Table 2. The control subjects had a mean FEV1 of 2.63 L or 112.1% predicted. There were significant differences in age, smoking history, and oxygen saturations between the control subjects
Discussion
We have shown for the first time that serum IP-10 increases from baseline to exacerbation in COPD specifically in exacerbations positive for HRV. Serum IP-10 has previously been shown to increase in virus-triggered acute asthma exacerbations,19 and we have now shown that in COPD exacerbations, sputum HRV load determined by quantitative RT-PCR correlates with IP-10 levels in the blood. Although HRV infection in most individuals is mild and self-limiting, in patients with COPD viral infection not
Acknowledgments
Author contributions: Dr Quint: contributed to the conception and design of the study, the acquisition of samples, ELISA processing, data analysis and interpretation, writing the first draft of the manuscript, and editing and revising the manuscript.
Dr Donaldson: contributed to the conception and design of the study, data analysis and interpretation, and editing and revising the manuscript.
Dr Goldring: contributed to acquisition of samples and editing and revising the manuscript.
Dr
References (0)
Cited by (0)
Funding/Support: This work was supported by the National Institutes of Health [Grant RO1 HL082578].
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestpubs.org/site/misc/reprints.xhtml).